262 related articles for article (PubMed ID: 15339960)
1. Medicare cost containment strategy targets several oncology drugs.
Twombly R
J Natl Cancer Inst; 2004 Sep; 96(17):1268-70. PubMed ID: 15339960
[No Abstract] [Full Text] [Related]
2. Medicare and drug pricing.
Iglehart JK
N Engl J Med; 2003 Apr; 348(16):1590-7. PubMed ID: 12700381
[No Abstract] [Full Text] [Related]
3. Prescription drug prices in Canada.
Gross D
Issue Brief (Public Policy Inst (Am Assoc Retired Pers)); 2003 Jun; (IB62):1-22. PubMed ID: 12807123
[No Abstract] [Full Text] [Related]
4. Limits on Medicare's ability to control rising spending on cancer drugs.
Bach PB
N Engl J Med; 2009 Feb; 360(6):626-33. PubMed ID: 19176475
[No Abstract] [Full Text] [Related]
5. Drug pricing and value in oncology.
Danzon PM; Taylor E
Oncologist; 2010; 15 Suppl 1():24-31. PubMed ID: 20237214
[TBL] [Abstract][Full Text] [Related]
6. When will the U.S. flinch at cancer drug prices?
Vanchieri C
J Natl Cancer Inst; 2005 May; 97(9):624-6. PubMed ID: 15870428
[No Abstract] [Full Text] [Related]
7. Patching up the dilapidated Medicare infrastructure: an examination of Part B expenditure targets as a cost containment remedy.
Caldwell JR
J Fla Med Assoc; 1989 May; 76(5):471-3. PubMed ID: 2693582
[No Abstract] [Full Text] [Related]
8. The shortage of essential chemotherapy drugs in the United States.
Gatesman ML; Smith TJ
N Engl J Med; 2011 Nov; 365(18):1653-5. PubMed ID: 22040130
[No Abstract] [Full Text] [Related]
9. Reimbursement for chemotherapy drugs used in office practice.
Bailes JS
Oncology (Williston Park); 1991 Oct; 5(10):27. PubMed ID: 1838268
[No Abstract] [Full Text] [Related]
10. Many new cancer drugs in the United Kingdom are facing negative NICE rulings.
Low E;
J Clin Oncol; 2007 Jun; 25(18):2635-6; author reply 2637-8. PubMed ID: 17577049
[No Abstract] [Full Text] [Related]
11. Reimbursement: current status and future outlook.
Bailes JS
Semin Oncol; 1994 Aug; 21(4 Suppl 7):118-22. PubMed ID: 8091237
[TBL] [Abstract][Full Text] [Related]
12. [Policies concerning pharmaceutical prices and reimbursement in Mexico, Organization for Co-operation and Economic Development. 2007].
Moïse P; Docteur E
Salud Publica Mex; 2008; 50 Suppl 4():S504-10. PubMed ID: 19082262
[No Abstract] [Full Text] [Related]
13. Navigating the business of oncology for 2008.
Crisafulli T
Semin Oncol; 2008 Feb; 35(1):1-5. PubMed ID: 18308138
[No Abstract] [Full Text] [Related]
14. Novel approaches to delivering value in oncology drugs.
Miller S
Clin Adv Hematol Oncol; 2016 Apr; 14(4):244-6. PubMed ID: 27166606
[No Abstract] [Full Text] [Related]
15. Medicare-approved drug discount cards and renal transplant patients: how much can these cards reduce prescription costs?
Chisholm MA; Marshall J; Smith KE; Garrett CJ; Turner JC
Clin Transplant; 2005 Jun; 19(3):357-63. PubMed ID: 15877798
[TBL] [Abstract][Full Text] [Related]
16. Pharmacoeconomic and clinical outcomes in oncology using oral chemotherapy.
Navarro RP; Morrow T; Baran R
Manag Care Interface; 2002 Jul; 15(7):55-62. PubMed ID: 12143298
[TBL] [Abstract][Full Text] [Related]
17. Medicare Part D: who wins, who loses?
Am Fam Physician; 2006 Feb; 73(3):401. PubMed ID: 16477886
[TBL] [Abstract][Full Text] [Related]
18. Reforming the payment system for medical oncology.
Bach PB
JAMA; 2013 Jul; 310(3):261-2. PubMed ID: 23817729
[No Abstract] [Full Text] [Related]
19. Saving money on prescription drugs.
Meadows M
FDA Consum; 2005; 39(5):18-26. PubMed ID: 16419288
[No Abstract] [Full Text] [Related]
20. Three Steps Toward a More Sustainable Path for Targeted Cancer Drugs.
Bekelman JE; Joffe S
JAMA; 2018 Jun; 319(21):2167-2168. PubMed ID: 29710240
[No Abstract] [Full Text] [Related]
[Next] [New Search]
